Chromatin, SF-1, and Ctbp Structural and Post-Translational Modifications Induced by ACTH/Camp Accelerate CYP17 Transcription Rate
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Matter of Degree We Ask Experts What Steers So Many Black Scientists Toward Earning a Master’S Before a Ph.D
Vol. 19 / No. 2 / February 2020 THE MEMBER MAGAZINE OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY A matter of degree We ask experts what steers so many black scientists toward earning a master’s before a Ph.D. Don’t wait a lifetime for a decision. C. elegans daf-2 mutants can live up to 40 days. JBC takes only 17 days on average to reach a fi rst decision about your paper. Learn more about fast, rigorous review at jbc.org. www.jbc.org NEWS FEATURES PERSPECTIVES 2 24 52 EDITOR’S NOTE A MATTER OF DEGREE A BEGINNER’S GUIDE TO MINORITY Picking up the slack What steers so many black scientists toward PROFESSOR HIRES 3 earning a master’s before a Ph.D.? NEWS FROM THE HILL 34 Acting to protect research integrity MEYERHOFF SCHOLARS A model for increasing diversity in STEM ANNUAL 4 MEETING MEMBER UPDATE 36 INCLUSIVE EXCELLENCE 7 36 A goal of lasting change NEWS 39 Program at Northeastern aims to fix the Honoring undergrads who promote diversity institution 8 40 RETROSPECTIVE FOR VULNERABLE POPULATIONS, Kensal E. van Holde (1928 – 2019) THE THORNY ETHICS OF GENETIC DATA COLLECTION 10 44 RESEARCH SPOTLIGHT JBC/TABOR AWARDS Understanding how arsenic changes 44 chromatin and causes cancer Award winners to speak at annual 13 24 meeting 45 NEWS Lavrsen finds endless possibilities Don’t wait a lifetime for a decision. Nan-Shan Chang has made WWOX in PTMs his life’s work 46 Varghese roams from forests to C. elegans daf-2 mutants can live up to 40 days. -
Medical Center
VanderbiltUniversityMedicalCenter Medical Center School of Medicine School of Nursing Hospital and Clinic Vanderbilt University 2002/2003 Containing general information and courses of study for the 2002/2003 session corrected to 1 July 2002 Nashville The University reserves the right, through its established procedures, to modify the require- ments for admission and graduation and to change other rules, regulations, and provisions, including those stated in this bulletin and other publications, and to refuse admission to any student, or to require the withdrawal of a student if it is determined to be in the interest of the student or the University. All students, full- or part-time, who are enrolled in Vanderbilt courses are subject to the same policies. Policies concerning non-curricular matters and concerning withdrawal for medical or emo- tional reasons can be found in the Student Handbook. EQUAL OPPORTUNITY In compliance with federal law, including the provisions of Title IX of the Education Amend- ments of 1972, Sections 503 and 504 of the Rehabilitation Act of 1973, and the Americans with Disabilities Act of 1990, Vanderbilt University does not discriminate on the basis of race, sex, religion, color, national or ethnic origin, age, disability, or military service in its administration of educational policies, programs, or activities; its admissions policies; scholarship and loan programs; athletic or other University-administered programs; or employment. In addition, the University does not discriminate on the basis of sexual orien- tation consistent with University non-discrimination policy. Inquiries or complaints should be directed to the Opportunity Development Officer, Baker Building, VU Station B #351809 Nashville, Tennessee 37235-1809. -
MCM2–7-Dependent Cohesin Loading During S Phase Promotes Sister-Chromatid Cohesion Ge Zheng1, Mohammed Kanchwala2, Chao Xing2,3,4, Hongtao Yu1*
RESEARCH ARTICLE MCM2–7-dependent cohesin loading during S phase promotes sister-chromatid cohesion Ge Zheng1, Mohammed Kanchwala2, Chao Xing2,3,4, Hongtao Yu1* 1Howard Hughes Medical Institute, Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, United States; 2Bioinformatics Lab, Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, United States; 3Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, United States; 4Department of Bioinformatics, University of Texas Southwestern Medical Center, Dallas, United States Abstract DNA replication transforms cohesin rings dynamically associated with chromatin into the cohesive form to establish sister-chromatid cohesion. Here, we show that, in human cells, cohesin loading onto chromosomes during early S phase requires the replicative helicase MCM2–7 and the kinase DDK. Cohesin and its loader SCC2/4 (NIPBL/MAU2 in humans) associate with DDK and phosphorylated MCM2–7. This binding does not require MCM2–7 activation by CDC45 and GINS, but its persistence on activated MCM2–7 requires fork-stabilizing replisome components. Inactivation of these replisome components impairs cohesin loading and causes interphase cohesion defects. Interfering with Okazaki fragment processing or nucleosome assembly does not impact cohesion. Therefore, MCM2–7-coupled cohesin loading promotes cohesion establishment, which occurs without Okazaki fragment maturation. We propose that the cohesin–loader complex bound to MCM2–7 is mobilized upon helicase activation, transiently held by the replisome, and deposited behind the replication fork to encircle sister chromatids and establish cohesion. *For correspondence: DOI: https://doi.org/10.7554/eLife.33920.001 [email protected] Competing interests: The authors declare that no Introduction competing interests exist. -
The Member Magazine of the American Society for Biochemistry and Molecular Biology
Vol. 14 / No. 3 / March 2015 THE MEMBER MAGAZINE OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY CONTENTS NEWS FEATURES PERSPECTIVES 2 14 50 PRESIDENT’S MESSAGE GIVING PARASITES THEIR DUE COORDINATES Conscience of commitment Chasing the North American Dream 20 4 STEAM 52 NEWS FROM THE HILL When our DNA is fair game CAREER INSIGHTS Gene-editing summit A Q&A with Clemencia Rojas 22 5 ANNUAL MEETING POINTERS 14 MEMBER UPDATE 32 8 ANNUAL AWARDS RETROSPECTIVE Marion Sewer (1972 – 2016) 22 10 JOURNAL NEWS 10 Turning on the thyroid 20 11 Using microRNAs to target cancer cells 12 A mouse model for Hajdu–Cheney syndrome 13 One gene, two proteins, one complex 8 32 50 2016 10 Annual Aards MARCH 2016 ASBMB TODAY 1 PRESIDENT’S MESSAGE THE MEMBER MAGAZINE OF THE AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY Conscience OFFICERS COUNCIL MEMBERS Steven McKnight Squire J. Booker of commitment President Karen G. Fleming Gregory Gatto Jr. Natalie Ahn Rachel Green By Steven McKnight President-Elect Susan Marqusee Karen Allen Jared Rutter Secretary Brenda Schulman Michael Summers very four years, my institution work with the American Society for Toni Antalis Treasurer requires that I take a course Biochemistry and Molecular Biol- ASBMB TODAY EDITORIAL ADVISORY BOARD E and exam regarding conicts ogy, I can help organize and attend EX-OFFICIO MEMBERS Charles Brenner of interest. Past courses have focused meetings, I can give lectures at other Squire Booker Chair primarily on nancial conicts of institutions, I can help found biotech- Wei Yang Michael Bradley Co-chairs, 2016 Annual Floyd “Ski” Chilton interest, but the course and test I took nology companies, and on and on — Meeting Program Cristy Gelling this past month had a new category so long as the activities have legitimate Committee Peter J. -
The Pharmacologist Vol. 54
Vol. 54 Number 3 2012 The Pharmacologist September ASPET Annual Mee ng at Experimental Biology 2013 Joint mee ng with the Bri sh Pharmacological Society; guest socie es include the Canadian Society for Pharmacology and Therapeu cs & the Behavioral Pharmacology Society Saturday, April 20 - Wednesday, April 24 Skyline from Boston Harbor Paul Revere Statue Fenway Park In this issue: Message from new ASPET President, John Lazo Informa on for ASPET Annual Mee ng at EB 2013 ASPET Membership Survey Results New ASPET Commi ee & Division Lists Congress Returns, Mulls NIH Funding MAPS Annual Mee ng Program Informa on Great Lakes Chapter Mee ng Abstracts Customs House Bunker Hill Monument The Pharmacologist 137 Volume 54 Number 3, 2012 The Pharmacologist is published and distributed by the American Society for Pharmacology and Experimental Contents Therapeu cs. Message from the President 139 EDITOR Gary Axelrod EDITORIAL ADVISORY BOARD ASPET Annual Mee ng at EB 2013 Stephen M. Lanier, PhD Charles P. France, PhD Important Dates 141 Kenneth E. Thummel, PhD COUNCIL Preliminary Program 141 President John S. Lazo, PhD Annual Mee ng News 153 President-Elect Richard R. Neubig, MD, PhD 4th GPCR Colloquium: April 24 - 25, 2013 154 Past President Lynn Wecker, PhD 2012 Annual Membership Survey Results 156 Secretary/Treasurer Edward T. Morgan, PhD New ASPET Commi ee Lists 158 Secretary/Treasurer-Elect Sandra P. Welch, PhD ASPET Commi ee Reorganiza on 160 Past Secretary/Treasurer Mary E. Vore, PhD Journals 162 Councilors Charles P. France, PhD Science Policy 164 Stephen M. Lanier, PhD Kenneth E. Thummel, PhD Chair, Board of Publica ons Trustees Integra ve and Organ System Sciences 166 James E. -
Bioinformatics Analysis of Differentially Expressed Genes and Pathways in the Development of Cervical Cancer Baojie Wu* and Shuyi Xi
Wu and Xi BMC Cancer (2021) 21:733 https://doi.org/10.1186/s12885-021-08412-4 RESEARCH Open Access Bioinformatics analysis of differentially expressed genes and pathways in the development of cervical cancer Baojie Wu* and Shuyi Xi Abstract Background: This study aimed to explore and identify key genes and signaling pathways that contribute to the progression of cervical cancer to improve prognosis. Methods: Three gene expression profiles (GSE63514, GSE64217 and GSE138080) were screened and downloaded from the Gene Expression Omnibus database (GEO). Differentially expressed genes (DEGs) were screened using the GEO2R and Venn diagram tools. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Gene set enrichment analysis (GSEA) was performed to analyze the three gene expression profiles. Moreover, a protein–protein interaction (PPI) network of the DEGs was constructed, and functional enrichment analysis was performed. On this basis, hub genes from critical PPI subnetworks were explored with Cytoscape software. The expression of these genes in tumors was verified, and survival analysis of potential prognostic genes from critical subnetworks was conducted. Functional annotation, multiple gene comparison and dimensionality reduction in candidate genes indicated the clinical significance of potential targets. Results: A total of 476 DEGs were screened: 253 upregulated genes and 223 downregulated genes. DEGs were enriched in 22 biological processes, 16 cellular components and 9 molecular functions in precancerous lesions and cervical cancer. DEGs were mainly enriched in 10 KEGG pathways. Through intersection analysis and data mining, 3 key KEGG pathways and related core genes were revealed by GSEA. -
Transdifferentiation of Human Mesenchymal Stem Cells
Transdifferentiation of Human Mesenchymal Stem Cells Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Julius-Maximilians-Universität Würzburg vorgelegt von Tatjana Schilling aus San Miguel de Tucuman, Argentinien Würzburg, 2007 Eingereicht am: Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Martin J. Müller Gutachter: PD Dr. Norbert Schütze Gutachter: Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am: Hiermit erkläre ich ehrenwörtlich, dass ich die vorliegende Dissertation selbstständig angefertigt und keine anderen als die von mir angegebenen Hilfsmittel und Quellen verwendet habe. Des Weiteren erkläre ich, dass diese Arbeit weder in gleicher noch in ähnlicher Form in einem Prüfungsverfahren vorgelegen hat und ich noch keinen Promotionsversuch unternommen habe. Gerbrunn, 4. Mai 2007 Tatjana Schilling Table of contents i Table of contents 1 Summary ........................................................................................................................ 1 1.1 Summary.................................................................................................................... 1 1.2 Zusammenfassung..................................................................................................... 2 2 Introduction.................................................................................................................... 4 2.1 Osteoporosis and the fatty degeneration of the bone marrow..................................... 4 2.2 Adipose and bone -
Activation of WD Repeat and High-Mobility Group Box DNA Binding Protein 1 in Pulmonary and Esophageal Carcinogenesis
Published OnlineFirst December 22, 2009; DOI: 10.1158/1078-0432.CCR-09-1405 Clinical Imaging, Diagnosis, Prognosis Cancer Research Activation of WD Repeat and High-Mobility Group Box DNA Binding Protein 1 in Pulmonary and Esophageal Carcinogenesis Nagato Sato1,2, Junkichi Koinuma1, Masahiro Fujita3, Masao Hosokawa3, Tomoo Ito4, Eiju Tsuchiya5, Satoshi Kondo2, Yusuke Nakamura1, and Yataro Daigo1,6 Abstract Purpose: We attempted to identify novel biomarkers and therapeutic targets for lung and esophageal cancers. Experimental Design: We screened for genes that were overexpressed in a large proportion of lung and esophageal carcinomas using a cDNA microarray representing 27,648 genes or expressed sequence tags. A gene encoding WDHD1, a WD repeat and high-mobility group box DNA binding protein 1, was selected as a candidate. Tumor tissue microarray containing 267 archival non–small cell lung cancers and 283 esophageal squamous cell carcinomas (ESCC) was used to investigate the clinicopathologic significance of WDHD1 expression. The role of WDHD1 in cancer cell growth and/or survival was examined by small interfering RNA experiments and cell growth assays. The mechanism of WDHD1 activation through its phosphorylation in cancer cells was examined by immunoprecipitation and kinase assays. Results: Positive WDHD1 immunostaining was associated with a poor prognosis for patients with non–small cell lung cancer (P = 0.0403) as well as ESCC (P = 0.0426). Multivariate analysis indicated it to be an independent prognostic factor for ESCC (P = 0.0104). Suppression of WDHD1 expression with small interfering RNAs effectively suppressed lung and esophageal cancer cell growth. In addition, induc- tion of the exogenous expression of WDHD1 promoted the growth of mammalian cells. -
Activation of WD Repeat and High-Mobility Group Box DNA Binding Protein 1 in Pulmonary and Esophageal Carcinogenesis
Published OnlineFirst December 22, 2009; DOI: 10.1158/1078-0432.CCR-09-1405 Clinical Imaging, Diagnosis, Prognosis Cancer Research Activation of WD Repeat and High-Mobility Group Box DNA Binding Protein 1 in Pulmonary and Esophageal Carcinogenesis Nagato Sato1,2, Junkichi Koinuma1, Masahiro Fujita3, Masao Hosokawa3, Tomoo Ito4, Eiju Tsuchiya5, Satoshi Kondo2, Yusuke Nakamura1, and Yataro Daigo1,6 Abstract Purpose: We attempted to identify novel biomarkers and therapeutic targets for lung and esophageal cancers. Experimental Design: We screened for genes that were overexpressed in a large proportion of lung and esophageal carcinomas using a cDNA microarray representing 27,648 genes or expressed sequence tags. A gene encoding WDHD1, a WD repeat and high-mobility group box DNA binding protein 1, was selected as a candidate. Tumor tissue microarray containing 267 archival non–small cell lung cancers and 283 esophageal squamous cell carcinomas (ESCC) was used to investigate the clinicopathologic significance of WDHD1 expression. The role of WDHD1 in cancer cell growth and/or survival was examined by small interfering RNA experiments and cell growth assays. The mechanism of WDHD1 activation through its phosphorylation in cancer cells was examined by immunoprecipitation and kinase assays. Results: Positive WDHD1 immunostaining was associated with a poor prognosis for patients with non–small cell lung cancer (P = 0.0403) as well as ESCC (P = 0.0426). Multivariate analysis indicated it to be an independent prognostic factor for ESCC (P = 0.0104). Suppression of WDHD1 expression with small interfering RNAs effectively suppressed lung and esophageal cancer cell growth. In addition, induc- tion of the exogenous expression of WDHD1 promoted the growth of mammalian cells. -
Cell Cycle Arrest Through Indirect Transcriptional Repression by P53: I Have a DREAM
Cell Death and Differentiation (2018) 25, 114–132 Official journal of the Cell Death Differentiation Association OPEN www.nature.com/cdd Review Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM Kurt Engeland1 Activation of the p53 tumor suppressor can lead to cell cycle arrest. The key mechanism of p53-mediated arrest is transcriptional downregulation of many cell cycle genes. In recent years it has become evident that p53-dependent repression is controlled by the p53–p21–DREAM–E2F/CHR pathway (p53–DREAM pathway). DREAM is a transcriptional repressor that binds to E2F or CHR promoter sites. Gene regulation and deregulation by DREAM shares many mechanistic characteristics with the retinoblastoma pRB tumor suppressor that acts through E2F elements. However, because of its binding to E2F and CHR elements, DREAM regulates a larger set of target genes leading to regulatory functions distinct from pRB/E2F. The p53–DREAM pathway controls more than 250 mostly cell cycle-associated genes. The functional spectrum of these pathway targets spans from the G1 phase to the end of mitosis. Consequently, through downregulating the expression of gene products which are essential for progression through the cell cycle, the p53–DREAM pathway participates in the control of all checkpoints from DNA synthesis to cytokinesis including G1/S, G2/M and spindle assembly checkpoints. Therefore, defects in the p53–DREAM pathway contribute to a general loss of checkpoint control. Furthermore, deregulation of DREAM target genes promotes chromosomal instability and aneuploidy of cancer cells. Also, DREAM regulation is abrogated by the human papilloma virus HPV E7 protein linking the p53–DREAM pathway to carcinogenesis by HPV.Another feature of the pathway is that it downregulates many genes involved in DNA repair and telomere maintenance as well as Fanconi anemia. -
Allele-Specific Expression of Parkinson's Disease Susceptibility
www.nature.com/scientificreports OPEN Allele‑specifc expression of Parkinson’s disease susceptibility genes in human brain Margrete Langmyhr1,2, Sandra Pilar Henriksen1, Chiara Cappelletti3, Wilma D. J. van de Berg4, Lasse Pihlstrøm1 & Mathias Toft1,2* Genome‑wide association studies have identifed genetic variation in genomic loci associated with susceptibility to Parkinson’s disease (PD), the most common neurodegenerative movement disorder worldwide. We used allelic expression profling of genes located within PD‑associated loci to identify cis‑regulatory variation afecting gene expression. DNA and RNA were extracted from post‑mortem superior frontal gyrus tissue and whole blood samples from PD patients and controls. The relative allelic expression of transcribed SNPs in 12 GWAS risk genes was analysed by real‑time qPCR. Allele‑ specifc expression was identifed for 9 out of 12 genes tested (GBA, TMEM175, RAB7L1, NUCKS1, MCCC1, BCKDK, ZNF646, LZTS3, and WDHD1) in brain tissue samples. Three genes (GPNMB, STK39 and SIPA1L2) did not show signifcant allele‑specifc efects. Allele‑specifc efects were confrmed in whole blood for three genes (BCKDK, LZTS3 and MCCC1), whereas two genes (RAB7L1 and NUCKS1) showed brain‑specifc allelic expression. Our study supports the hypothesis that changes to the cis- regulation of gene expression is a major mechanism behind a large proportion of genetic associations in PD. Interestingly, allele‑specifc expression was also observed for coding variants believed to be causal variants (GBA and TMEM175), indicating that splicing and other regulatory mechanisms may be involved in disease development. Variants altering gene expression play a critical role in human health and disease and may be particularly impor- tant in neurological disorders as small changes in the gene expression of neurons may afect disease risk 1,2. -
Leveraging Models of Cell Regulation and GWAS Data in Integrative Network-Based Association Studies
PERSPECTIVE Leveraging models of cell regulation and GWAS data in integrative network-based association studies Andrea Califano1–3,11, Atul J Butte4,5, Stephen Friend6, Trey Ideker7–9 & Eric Schadt10,11 Over the last decade, the genome-wide study of both heritable and straightforward: within the space of all possible genetic and epigenetic somatic human variability has gone from a theoretical concept to a variants, those contributing to a specific trait or disease likely have broadly implemented, practical reality, covering the entire spectrum some coalescent properties, allowing their effect to be functionally of human disease. Although several findings have emerged from these canalized via the cell communication and cell regulatory machin- studies1, the results of genome-wide association studies (GWAS) have ery that allows distinct cells to interact and regulates their behavior. been mostly sobering. For instance, although several genes showing Notably, contrary to random networks, whose output is essentially medium-to-high penetrance within heritable traits were identified by unconstrained, regulatory networks produced by adaptation to spe- these approaches, the majority of heritable genetic risk factors for most cific fitness landscapes are optimized to produce only a finite number common diseases remain elusive2–7. Additionally, due to impractical of well-defined outcomes as a function of a very large number of exog- requirements for cohort size8 and lack of methodologies to maximize enous and endogenous signals. Thus, if a comprehensive and accurate power for such detections, few epistatic interactions and low-pen- map of all intra- and intercellular molecular interactions were avail- etrance variants have been identified9. At the opposite end of the able, then genetic and epigenetic events implicated in a specific trait or germline versus somatic event spectrum, considering that tumor cells disease should cluster in subnetworks of closely interacting genes.